Perspective Therapeutics Inc (CATX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Perspective Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Perspective Therapeutics Inc 's ROA in the second quarter of 2026?
Perspective Therapeutics Inc recorded a cumulative net loss of $-13 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -3.13%.
However, within the Healthcare sector Perspective Therapeutics Inc achieved the highest return on assets. While the total ranking for ROA unchanged, relative to the first quarter of 2026 at no. .
Perspective Therapeutics Innovative Radiopharmaceutical Data Accepted for Presentation at 2025 ASCO Annual MeetingApril 23, 2025 SEATTLE Perspective Therapeutics, a leading radiopharmaceutical company dedicated to pioneering cutting-edge treatments for a wide array of cancers, announced today that its pioneering research data on the ²¹²PbVMT NET and ²¹²PbVMT01 programs have achieved the prestigious milestone of being accepted for presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This significant annual event, which gathers thousands of oncology professionals from around the globe, will take place from May 30 to June 3, 2025, in Chicago, Illinois.The acceptance of Perspective Therapeutics data into the ASCO Annual Meeting underscores the transformative potential of its innovative radiopharmaceutical approach, which harnesses the radioactive isotope lead-212 (²¹²Pb) in combination with targeted NET (neuroendocrine tumor) therapies. These groundbreaking programs, namely ²¹²PbVMT NET and ²¹²PbVMT01, aim to deliver potent anti-cancer effects by selectively targeting cancerous cells while minimizing collateral impact on healthy tissues.
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a forward-thinking company in the field of radiopharmaceuticals, has reached a significant milestone with the commencement of shipments and patient dosing from its newly inaugurated manufacturing facility in Somerset, New Jersey. As the company continues to spearhead innovative treatments for various forms of cancer, this development signals a pivotal expansion in its manufacturing capabilities, promising enhanced production capacity and potentially transformative impacts on cancer treatment approaches. Significant Development in Radiopharmaceutical Manufacturing Positioned as a leader in oncology-focused radiopharmaceutical technology, Perspective Therapeutics has celebrated the first shipment from its second state-of-the-art facility. The manufacturing unit is dedicated to producing 203Pb- and 212Pb-labeled radiopharmaceuticals, which are critical components in targeted radiation therapy, a cutting-edge method that delivers precise doses of radiation to cancer cells while minimizing damage to surrounding healthy tissue. This nuanced modality represents a significant advancement in cancer therapy, underlining the company’s commitment to improving treatment outcomes for patients globally.
Author: Affiliation: Your Institution Published in: CSIMarket.com Date: October 11, 2024 : The emergence of radiopharmaceutical therapies has invigorated the scientific community s efforts to address treatment-resistant cancers. Recently, Perspective Therapeutics presented promising initial results from their Phase 1/2a study of ^212PbVMT01 during the 21st International Congress of the Society for Melanoma Research held in New Orleans. This article outlines the potential implications of this first-in-class radiopharmaceutical therapy in the management of melanoma and other cancers. Innovative therapeutic strategies are essential to combating the persistent challenge posed by melanoma and other cancers. Perspective Therapeutics, a pioneering company in the field of radiopharmaceuticals, recently disclosed initial findings from their Phase 1/2a clinical trial of ^212PbVMT01. This novel compound, utilizing the alpha-emitting isotope lead-212, aims to provide a targeted therapy option that could address unmet needs in oncology, particularly for patients with advanced-stage melanoma.
Comment on CATX's ROA in the fiscal year ending 2025
In the fiscal year 2025 Perspective Therapeutics Inc 's ROA decreased compared to previous year to 0.3 %, due to deterioration of net income -62.18 % to $0.79 million, from $2.10 million a year ago, as CATX's assets were $266.97 million.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
